BIRC2 and prostate carcinoma: These results demonstrate that knockdown of XIAP and cIAP-1 effectively sensitizes the cells to TRAIL, indicating that both XIAP and cIAP-1 are involved in TRAIL-resistance, and that silencing XIAP and/or c-IAP1 can overcome such resistance in prostate cancer cells.